Eli Lilly and Walmart have partnered to offer in-store pickup of Zepbound (tirzepatide) single-dose vials through the LillyDirect platform by mid-November.
The collaboration marks the first time patients using LillyDirect, the company’s direct-to-consumer healthcare platform, will be able to access self-pay pricing for Zepbound vials at a retail pharmacy, according to an Oct. 29 news release.
LillyDirect’s self-pay pricing offers a 50% or greater discount compared to the list price of other incretin (GLP-1) medications for obesity, with pricing ranging from $349 per month for the recommended 2.5 mg starting dose to $499 for all other strengths through the Zepbound Self Pay Journey Program.
The Zepbound vials will be available to patients with a valid, on-label prescription, regardless of insurance status, the release said.
In the second quarter of 2025, approximately 35% of new Zepbound prescriptions were filled through LillyDirect’s self-pay option. The company said it plans to expand access to its medicines through additional direct-to-consumer channels.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
